hydromorphone Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
opioid receptor antagonists/agonists, morphinan derivates 1393 466-99-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • hydromorphone
  • dihydromorphinone
  • dihydromorphone
  • dimorphone
  • hydromorphon
  • hydromorphone hydrochloride
  • hydromorphone HCl
An opioid analgesic made from MORPHINE and used mainly as an analgesic. It has a shorter duration of action than morphine.
  • Molecular weight: 285.34
  • Formula: C17H19NO3
  • CLOGP: 0.72
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 1
  • TPSA: 49.77
  • ALOGS: -1.81
  • ROTB: 0

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
20 mg O
4 mg P
4 mg R

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 10 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 6 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.20 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 42 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 4.30 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 28 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.86 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2.30 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Jan. 11, 1984 FDA PURDUE PHARM PRODS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 379.72 9.80 1125 82421 242700 46359816
Temperature regulation disorder 192.84 9.80 102 83444 3258 46599258
Pneumonia viral 162.79 9.80 117 83429 6507 46596009
Pain 156.25 9.80 1416 82130 475532 46126984
Drug withdrawal syndrome 137.53 9.80 205 83341 27179 46575337
Food allergy 131.71 9.80 105 83441 6828 46595688
Pneumonia aspiration 128.81 9.80 215 83331 31390 46571126
Soft tissue disorder 126.56 9.80 84 83462 4102 46598414
Unresponsive to stimuli 124.68 9.80 214 83332 31960 46570556
Coeliac disease 124.53 9.80 103 83443 7058 46595458
Drug dependence 117.61 9.80 161 83385 19740 46582776
Delirium 101.31 9.80 213 83333 37015 46565501
Somnolence 100.99 9.80 549 82997 155972 46446544
Synovitis 100.53 9.80 288 83258 60787 46541729
Bursitis 100.28 9.80 149 83397 19693 46582823
Immunodeficiency 97.78 9.80 119 83427 12987 46589529
Hyperaesthesia 87.49 9.80 88 83458 7768 46594748
Respiratory depression 86.01 9.80 105 83441 11495 46591021
Respiratory rate decreased 81.19 9.80 57 83489 3053 46599463
Extremity contracture 76.57 9.80 39 83507 1150 46601366
Constipation 73.35 9.80 548 82998 173549 46428967
Inadequate analgesia 71.96 9.80 51 83495 2773 46599743
Alopecia 69.21 9.80 115 83431 162299 46440217
Arthritis 67.62 9.80 296 83250 77020 46525496
Coma 66.79 9.80 243 83303 58106 46544410
Pemphigus 65.02 9.80 4 83542 45270 46557246
Hypermobility syndrome 64.22 9.80 29 83517 650 46601866
Oral pain 59.63 9.80 135 83411 24662 46577854
Ankylosing spondylitis 56.59 9.80 65 83481 6672 46595844
Back pain 56.31 9.80 599 82947 209440 46393076
Injection site erythema 55.62 9.80 32 83514 74395 46528121
Fibromyalgia 54.31 9.80 166 83380 36297 46566219
Drug interaction 51.04 9.80 189 83357 202905 46399611
Nausea 49.96 9.80 1594 81952 685860 45916656
Herpes zoster 49.88 9.80 247 83299 67625 46534891
Sedation 48.84 9.80 119 83427 22791 46579725
Malignant neoplasm progression 47.51 9.80 236 83310 64690 46537826
Medical device site pain 46.74 9.80 17 83529 212 46602304
Exposure during pregnancy 46.65 9.80 76 83470 108136 46494380
Drug abuse 46.06 9.80 230 83316 63178 46539338
Respiratory arrest 45.82 9.80 149 83397 33667 46568849
Device related thrombosis 45.48 9.80 28 83518 1199 46601317
Intentional overdose 44.30 9.80 31 83515 64913 46537603
Narcotic bowel syndrome 43.39 9.80 14 83532 118 46602398
Sickle cell anaemia with crisis 43.14 9.80 44 83502 3948 46598568
Myocardial infarction 42.50 9.80 68 83478 97460 46505056
Implant site extravasation 42.29 9.80 20 83526 500 46602016
Overdose 41.76 9.80 319 83227 101660 46500856
Maternal exposure during pregnancy 41.48 9.80 75 83471 102474 46500042
Drug tolerance 41.37 9.80 39 83507 3179 46599337
Drug diversion 40.72 9.80 23 83523 838 46601678
Neoplasm progression 40.22 9.80 122 83424 26561 46575955
Injection site pain 40.17 9.80 82 83464 107070 46495446
Hepatic function abnormal 39.39 9.80 7 83539 34414 46568102
Injection site swelling 38.66 9.80 12 83534 40315 46562201
Renal impairment 38.27 9.80 46 83500 74326 46528190
Device expulsion 37.90 9.80 3 83543 27539 46574977
Glossodynia 37.80 9.80 16 83530 44357 46558159
Interstitial lung disease 37.80 9.80 25 83521 53924 46548592
Hereditary angioedema 37.80 9.80 48 83498 5468 46597048
Scar 37.73 9.80 73 83473 11946 46590570
Vomiting 37.34 9.80 1067 82479 451727 46150789
Cardiac failure congestive 37.19 9.80 67 83479 91683 46510833
Product dose omission issue 37.18 9.80 165 83381 168355 46434161
Abortion spontaneous 36.76 9.80 16 83530 43630 46558886
Completed suicide 36.69 9.80 411 83135 145509 46457007
Lactic acidosis 36.49 9.80 8 83538 33901 46568615
Drug reaction with eosinophilia and systemic symptoms 36.10 9.80 5 83541 29543 46572973
Hyponatraemia 35.93 9.80 80 83466 101252 46501264
Postmortem blood drug level increased 35.83 9.80 17 83529 428 46602088
Apnoea 35.49 9.80 54 83492 7285 46595231
Hyperhidrosis 35.25 9.80 277 83269 89031 46513485
Rash 34.00 9.80 442 83104 356070 46246446
Systemic lupus erythematosus 32.81 9.80 41 83505 65139 46537377
Pustular psoriasis 32.47 9.80 38 83508 3979 46598537
Hypertensive encephalopathy 31.94 9.80 18 83528 653 46601863
Mental status changes 31.90 9.80 144 83402 37944 46564572
Hepatocellular injury 31.70 9.80 7 83539 29515 46573001
Gastrooesophageal reflux disease 31.23 9.80 234 83312 74110 46528406
Compartment syndrome 31.15 9.80 27 83519 1972 46600544
Injection site reaction 31.12 9.80 24 83522 47825 46554691
Abdominal pain 30.68 9.80 580 82966 229451 46373065
Small intestinal obstruction 30.30 9.80 80 83466 16092 46586424
Injection site pruritus 29.81 9.80 17 83529 39726 46562790
Foetal exposure during pregnancy 29.74 9.80 9 83537 30738 46571778
Treatment failure 29.44 9.80 78 83468 93009 46509507
Rheumatoid factor negative 29.41 9.80 16 83530 541 46601975
Acute chest syndrome 29.07 9.80 16 83530 554 46601962
Rash erythematous 28.87 9.80 130 83416 34220 46568296
Neutropenia 28.77 9.80 145 83401 143059 46459457
Hepatitis 28.44 9.80 11 83535 32204 46570312
Cardiac failure 28.44 9.80 63 83483 79885 46522631
Head banging 27.57 9.80 14 83532 410 46602106
Toxicity to various agents 27.56 9.80 532 83014 211234 46391282
Anaphylactic reaction 27.52 9.80 176 83370 52936 46549580
Bursitis infective 27.12 9.80 20 83526 1157 46601359
No adverse event 26.61 9.80 14 83532 34217 46568299
Lower respiratory tract infection 26.34 9.80 36 83510 55053 46547463
Cough 25.55 9.80 276 83270 229973 46372543
Intentional self-injury 25.40 9.80 6 83540 24160 46578356
Infection 25.31 9.80 357 83189 133235 46469281
Tenderness 25.27 9.80 77 83469 16804 46585712
Postoperative ileus 25.22 9.80 14 83532 493 46602023
Rheumatoid arthritis 24.96 9.80 584 82962 239631 46362885
Acute kidney injury 24.88 9.80 286 83260 235569 46366947
Rhesus antigen positive 24.84 9.80 9 83537 111 46602405
Peripheral swelling 24.77 9.80 409 83137 157662 46444854
Platelet aggregation inhibition 24.55 9.80 9 83537 115 46602401
Infusion site mass 24.37 9.80 17 83529 901 46601615
Anti-cyclic citrullinated peptide antibody positive 23.96 9.80 3 83543 19142 46583374
Spinal cord compression 23.59 9.80 31 83515 3653 46598863
Immunoglobulins decreased 23.24 9.80 16 83530 830 46601686
Cancer pain 22.91 9.80 25 83521 2425 46600091
Pregnancy 22.77 9.80 10 83536 27127 46575389
Screaming 22.23 9.80 28 83518 3163 46599353
Abdominal discomfort 22.07 9.80 169 83377 150996 46451520
Post procedural complication 21.93 9.80 70 83476 15659 46586857
Overwork 21.91 9.80 7 83539 57 46602459
Eosinophilia 21.79 9.80 4 83542 19213 46583303
Intestinal pseudo-obstruction 21.66 9.80 14 83532 653 46601863
Obstruction 21.51 9.80 20 83526 1602 46600914
Amputation stump pain 21.11 9.80 6 83540 31 46602485
Breast cancer metastatic 21.05 9.80 63 83483 13615 46588901
Migraine 20.76 9.80 204 83342 69822 46532694
Antidepressant drug level above therapeutic 20.72 9.80 11 83535 354 46602162
Localised infection 20.69 9.80 91 83455 23710 46578806
Malignant polyp 20.56 9.80 9 83537 187 46602329
Blood cholesterol increased 20.36 9.80 132 83414 39881 46562635
Drug intolerance 20.35 9.80 373 83173 146676 46455840
Syncope 19.98 9.80 108 83438 104695 46497821
Blood pressure systolic increased 19.90 9.80 103 83443 28684 46573832
Respiratory syncytial virus infection 19.83 9.80 33 83513 4802 46597714
Extradural haematoma 19.75 9.80 18 83528 1405 46601111
Breast cancer 19.57 9.80 32 83514 45486 46557030
Bronchomalacia 19.53 9.80 8 83538 140 46602376
Cholestasis 19.47 9.80 12 83534 26881 46575635
Emotional distress 19.27 9.80 107 83439 30600 46571916
Wrong technique in product usage process 19.25 9.80 43 83503 54379 46548137
Substance abuse 19.22 9.80 30 83516 4137 46598379
Diarrhoea 18.96 9.80 814 82732 558788 46043728
Foreign body embolism 18.55 9.80 4 83542 4 46602512
Pericarditis 18.28 9.80 10 83536 23917 46578599
Vitamin K deficiency 18.25 9.80 11 83535 453 46602063
Ligament pain 18.11 9.80 8 83538 170 46602346
Premature baby 18.07 9.80 5 83541 18107 46584409
Epilepsy 18.02 9.80 10 83536 23728 46578788
Dizziness 17.91 9.80 468 83078 339946 46262570
Accidental overdose 17.66 9.80 77 83469 19989 46582527
Alveolitis 17.43 9.80 22 83524 2491 46600025
Psoriasis 17.29 9.80 77 83469 78527 46523989
Fluid retention 17.28 9.80 153 83393 50893 46551623
Defaecation disorder 17.00 9.80 9 83537 288 46602228
Therapeutic product effect incomplete 16.92 9.80 214 83332 77939 46524577
Metastases to bone 16.88 9.80 69 83477 17407 46585109
Hepatic cirrhosis 16.72 9.80 64 83482 15668 46586848
Pulmonary embolism 16.65 9.80 280 83266 108305 46494211
Plasma cell myeloma 16.47 9.80 136 83410 44342 46558174
Allodynia 16.45 9.80 11 83535 544 46601972
Bradycardia 16.43 9.80 62 83484 66236 46536280
Red cell distribution width increased 16.40 9.80 40 83506 7664 46594852
Blood immunoglobulin M decreased 16.20 9.80 12 83534 699 46601817
Faecal volume decreased 16.05 9.80 7 83539 144 46602372
Limb mass 15.99 9.80 21 83525 2473 46600043
Carbohydrate antigen 19-9 increased 15.88 9.80 7 83539 148 46602368
Joint dislocation 15.79 9.80 50 83496 11136 46591380
Angioedema 15.69 9.80 29 83517 39313 46563203
Status epilepticus 15.66 9.80 3 83543 13976 46588540
Palpitations 15.60 9.80 103 83443 95156 46507360
Dry eye 15.33 9.80 19 83527 30303 46572213
Photophobia 15.32 9.80 59 83487 14485 46588031
Orthostatic hypotension 15.25 9.80 13 83533 24645 46577871
Osteoporosis 14.95 9.80 124 83422 40484 46562032
Opiates positive 14.80 9.80 8 83538 267 46602249
Adiposis dolorosa 14.80 9.80 8 83538 267 46602249
Rash pruritic 14.79 9.80 36 83510 44179 46558337
Drug eruption 14.78 9.80 10 83536 21319 46581197
White blood cell count decreased 14.76 9.80 129 83417 112102 46490414
Heart rate increased 14.61 9.80 201 83345 74590 46527926
Bone marrow failure 14.58 9.80 19 83527 29650 46572866
Intestinal metastasis 14.56 9.80 5 83541 52 46602464
Incorrect route of product administration 14.52 9.80 63 83483 16320 46586196
Multiple sclerosis relapse 14.32 9.80 34 83512 42091 46560425
Apnoeic attack 14.30 9.80 8 83538 286 46602230
Ischaemic stroke 14.29 9.80 6 83540 16716 46585800
Virologic failure 14.27 9.80 18 83528 2037 46600479
Toxicologic test abnormal 14.17 9.80 11 83535 688 46601828
Cerebrospinal fluid leakage 14.15 9.80 12 83534 851 46601665
Toxic leukoencephalopathy 14.12 9.80 10 83536 543 46601973
Caesarean section 14.12 9.80 6 83540 16597 46585919
Liver function test abnormal 14.06 9.80 136 83410 46351 46556165
Device power source issue 13.96 9.80 9 83537 418 46602098
Foreign body reaction 13.92 9.80 5 83541 60 46602456
Silicon granuloma 13.91 9.80 3 83543 3 46602513
Device failure 13.83 9.80 32 83514 5927 46596589
Pneumocystis jirovecii pneumonia 13.81 9.80 5 83541 15243 46587273
Neuralgia 13.74 9.80 75 83471 21308 46581208
Soft tissue swelling 13.73 9.80 12 83534 886 46601630
Psychiatric symptom 13.73 9.80 27 83519 4470 46598046
Exostosis 13.70 9.80 45 83501 10218 46592298
Atelectasis 13.52 9.80 68 83478 18722 46583794
Device infusion issue 13.52 9.80 13 83533 1086 46601430
Procedural pain 13.50 9.80 53 83493 13126 46589390
Melaena 13.42 9.80 18 83528 27754 46574762
Pulmonary arterial hypertension 13.37 9.80 16 83530 25912 46576604
Substance dependence 13.36 9.80 7 83539 219 46602297
Eye operation 13.36 9.80 16 83530 1716 46600800
Suicide attempt 13.29 9.80 52 83494 54984 46547532
Cytomegalovirus infection 13.27 9.80 8 83538 18136 46584380
Rib fracture 13.22 9.80 68 83478 18886 46583630
Red blood cell sedimentation rate abnormal 13.19 9.80 4 83542 13645 46588871
Dyspnoea 13.16 9.80 772 82774 514776 46087740
Toe amputation 12.91 9.80 17 83529 2007 46600509
Pancreatitis 12.88 9.80 127 83419 43500 46559016
Alanine aminotransferase increased 12.85 9.80 99 83447 88352 46514164
Tachyphylaxis 12.75 9.80 7 83539 241 46602275
Presyncope 12.71 9.80 15 83531 24439 46578077
Implant site haematoma 12.67 9.80 5 83541 79 46602437
Drug ineffective 12.66 9.80 1391 82155 676447 45926069
Respiratory failure 12.58 9.80 239 83307 94577 46507939
Asthma 12.58 9.80 232 83314 91310 46511206
Balance disorder 12.56 9.80 66 83480 64455 46538061
Respiratory rate increased 12.55 9.80 47 83499 11386 46591130
Injection site urticaria 12.52 9.80 3 83543 11964 46590552
Cholangitis sclerosing 12.47 9.80 12 83534 1003 46601513
Ileus 12.40 9.80 54 83492 14010 46588506
Perineal pain 12.39 9.80 7 83539 255 46602261
Bacteraemia 12.16 9.80 54 83492 14125 46588391
Swollen tongue 12.15 9.80 21 83525 29211 46573305
Visual acuity reduced 12.11 9.80 13 83533 22100 46580416
Intestinal obstruction 12.05 9.80 84 83462 25991 46576525
Hypercapnia 12.04 9.80 26 83520 4600 46597916
Wound infection bacterial 12.01 9.80 8 83538 393 46602123
Gastrointestinal haemorrhage 12.00 9.80 85 83461 77288 46525228
Transient ischaemic attack 12.00 9.80 28 83518 34875 46567641
Ocular procedural complication 11.96 9.80 7 83539 273 46602243
Joint swelling 11.90 9.80 385 83161 165688 46436828
Implant site pain 11.90 9.80 17 83529 2167 46600349
Eastern Cooperative Oncology Group performance status worsened 11.83 9.80 8 83538 403 46602113
Shock 11.78 9.80 13 83533 21832 46580684
Learning disability 11.78 9.80 5 83541 96 46602420
Serotonin syndrome 11.78 9.80 79 83467 24141 46578375
Chest discomfort 11.76 9.80 104 83442 90165 46512351
Dental caries 11.67 9.80 43 83503 10336 46592180
Injection site warmth 11.67 9.80 5 83541 13767 46588749
Intestinal resection 11.63 9.80 17 83529 2213 46600303
Sopor 11.60 9.80 11 83535 19817 46582699
Biliary tract infection 11.57 9.80 8 83538 418 46602098
Sinusitis 11.56 9.80 163 83383 129605 46472911
Ocular hyperaemia 11.46 9.80 11 83535 19699 46582817
Electrocardiogram QT prolonged 11.45 9.80 50 83496 51275 46551241
Death 11.45 9.80 721 82825 334827 46267689
Implant site infection 11.43 9.80 11 83535 920 46601596
Nerve block 11.40 9.80 8 83538 428 46602088
Hypocalcaemia 11.36 9.80 19 83527 26766 46575750
Anaesthetic complication neurological 11.27 9.80 6 83540 194 46602322
Hypoxia 11.24 9.80 142 83404 51696 46550820
Eye irritation 11.23 9.80 8 83538 16606 46585910
Device computer issue 11.18 9.80 3 83543 12 46602504
Hypertension 11.10 9.80 267 83279 196089 46406427
Respiratory tract inflammation 11.09 9.80 8 83538 447 46602069
Accidental death 11.07 9.80 15 83531 1820 46600696
Multiple sclerosis 11.06 9.80 17 83529 24774 46577742
Seasonal allergy 11.05 9.80 5 83541 13329 46589187
Encephalitis brain stem 10.95 9.80 5 83541 115 46602401
Cardio-respiratory arrest 10.93 9.80 159 83387 59710 46542806
Intracranial hypotension 10.92 9.80 7 83539 322 46602194
Coronary artery disease 10.88 9.80 28 83518 33724 46568792
Monoclonal gammopathy 10.86 9.80 9 83537 618 46601898
Cerebrovascular accident 10.83 9.80 122 83424 100917 46501599
Skin laceration 10.64 9.80 63 83483 18439 46584077
Intestinal perforation 10.61 9.80 43 83503 10808 46591708
Groin pain 10.57 9.80 38 83508 9027 46593489
Product substitution issue 10.48 9.80 7 83539 15024 46587492
Product storage error 10.45 9.80 4 83542 11788 46590728
Blood triglycerides increased 10.44 9.80 4 83542 11779 46590737
Injection site bruising 10.42 9.80 31 83515 35605 46566911
Stevens-Johnson syndrome 10.37 9.80 16 83530 23281 46579235
Drug use disorder 10.34 9.80 18 83528 2717 46599799
Portal vein thrombosis 10.34 9.80 17 83529 2450 46600066
Lethargy 10.18 9.80 138 83408 51033 46551483
Blood pressure fluctuation 10.17 9.80 91 83455 30357 46572159
Rheumatoid factor positive 10.16 9.80 13 83533 20448 46582068
Brain injury 10.11 9.80 29 83517 6121 46596395
Agranulocytosis 10.11 9.80 15 83531 22170 46580346
Product name confusion 10.09 9.80 4 83542 64 46602452
COVID-19 10.08 9.80 11 83535 18564 46583952
Feeling of body temperature change 10.05 9.80 23 83523 4229 46598287
Hypersplenism 10.05 9.80 6 83540 243 46602273
Live birth 10.03 9.80 3 83543 10327 46592189
Eye disorder 9.94 9.80 61 83485 18080 46584436
Abortion induced 9.93 9.80 3 83543 10257 46592259
Miliaria 9.93 9.80 10 83536 884 46601632
Pancreatolithiasis 9.91 9.80 6 83540 249 46602267
Poor venous access 9.84 9.80 35 83511 8273 46594243

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pain 227.60 10.59 687 46032 171954 29733805
Hyperaesthesia 160.47 10.59 88 46631 3485 29902274
Drug dependence 150.91 10.59 176 46543 21119 29884640
Drug withdrawal syndrome 134.20 10.59 160 46559 19649 29886110
Sedation 112.14 10.59 133 46586 16240 29889519
Respiratory depression 74.76 10.59 91 46628 11412 29894347
Nausea 74.08 10.59 747 45972 296210 29609549
Back pain 64.16 10.59 323 46396 102273 29803486
Serotonin syndrome 62.11 10.59 105 46614 17786 29887973
Mental status changes 61.78 10.59 161 46558 36918 29868841
Toxicologic test abnormal 60.84 10.59 26 46693 587 29905172
Unresponsive to stimuli 59.50 10.59 129 46590 26290 29879469
Drug abuse 58.24 10.59 268 46451 81804 29823955
Drug tolerance 52.63 10.59 36 46683 2126 29903633
Respiratory arrest 51.80 10.59 130 46589 29128 29876631
Respiratory rate decreased 50.89 10.59 33 46686 1782 29903977
Inadequate analgesia 49.72 10.59 38 46681 2670 29903089
Vomiting 49.03 10.59 541 46178 219277 29686482
Constipation 48.05 10.59 321 46398 112585 29793174
Abdominal pain 46.96 10.59 367 46352 135287 29770472
Medical device site pain 45.87 10.59 13 46706 78 29905681
Postmortem blood drug level abnormal 45.33 10.59 16 46703 211 29905548
Interstitial lung disease 43.02 10.59 20 46699 60177 29845582
Appendicolith 42.27 10.59 23 46696 896 29904863
Drug hypersensitivity 41.58 10.59 214 46505 68305 29837454
Chest injury 41.22 10.59 26 46693 1338 29904421
Walking aid user 39.81 10.59 26 46693 1421 29904338
Postoperative ileus 39.61 10.59 20 46699 667 29905092
Prostate cancer metastatic 39.46 10.59 44 46675 5023 29900736
Arachnoiditis 38.91 10.59 16 46703 327 29905432
Delirium 38.46 10.59 145 46574 40486 29865273
Device power source issue 37.68 10.59 15 46704 281 29905478
Painful respiration 37.48 10.59 24 46695 1268 29904491
Substance abuse 36.79 10.59 50 46669 6990 29898769
Toxicity to various agents 35.82 10.59 428 46291 176755 29729004
Cardiac failure 35.33 10.59 47 46672 83371 29822388
Drug interaction 35.12 10.59 176 46543 199392 29706367
Myoclonus 33.46 10.59 68 46651 13244 29892515
Overdose 31.29 10.59 232 46487 84105 29821654
Myocardial infarction 30.15 10.59 98 46621 125527 29780232
Product dose omission issue 29.21 10.59 62 46657 91569 29814190
Hepatocellular injury 28.99 10.59 3 46716 25468 29880291
Muscle spasticity 28.88 10.59 38 46681 5150 29900609
Oxygen saturation decreased 28.69 10.59 139 46580 43301 29862458
Malignant neoplasm progression 28.62 10.59 202 46517 72085 29833674
Lethargy 27.22 10.59 128 46591 39391 29866368
Hepatic function abnormal 26.92 10.59 16 46703 41929 29863830
Xyphoid retraction 26.23 10.59 10 46709 166 29905593
Anaesthetic complication neurological 26.13 10.59 12 46707 323 29905436
Acute kidney injury 25.83 10.59 288 46431 273554 29632205
Hyperhidrosis 24.56 10.59 184 46535 66906 29838853
Infusion site mass 23.43 10.59 10 46709 225 29905534
Stress 23.26 10.59 77 46642 20158 29885601
Seizure like phenomena 23.20 10.59 13 46706 537 29905222
Withdrawal syndrome 23.15 10.59 53 46666 11197 29894562
Cardiac failure congestive 22.27 10.59 63 46656 84344 29821415
Hypoxia 22.11 10.59 139 46580 47715 29858044
Apnoea 22.07 10.59 37 46682 6221 29899538
Victim of child abuse 21.41 10.59 10 46709 280 29905479
Renal impairment 21.36 10.59 64 46655 84120 29821639
Death 21.25 10.59 717 46002 356566 29549193
Immune-mediated hepatitis 21.24 10.59 16 46703 1100 29904659
Rhabdomyolysis 21.12 10.59 42 46677 63538 29842221
Spinal shock 20.94 10.59 5 46714 13 29905746
Substance dependence 20.79 10.59 11 46708 405 29905354
Hot flush 20.71 10.59 60 46659 14620 29891139
Oesophageal infection 20.29 10.59 9 46710 223 29905536
Disease progression 20.27 10.59 202 46517 79672 29826087
Cerebrovascular accident 20.09 10.59 65 46654 83412 29822347
Lymphoedema 20.05 10.59 26 46693 3473 29902286
Coronary artery disease 20.04 10.59 29 46690 49683 29856076
Cholestasis 19.92 10.59 7 46712 24943 29880816
Lactic acidosis 19.89 10.59 12 46707 31201 29874558
Plasma cell myeloma 19.77 10.59 147 46572 53315 29852444
Needle issue 19.70 10.59 27 46692 3805 29901954
Neoplasm progression 19.32 10.59 67 46652 17956 29887803
Blood creatine phosphokinase increased 19.28 10.59 24 46695 43824 29861935
Sickle cell anaemia with crisis 18.95 10.59 21 46698 2381 29903378
Failure to thrive 18.90 10.59 40 46679 8014 29897745
Delirium tremens 18.32 10.59 11 46708 518 29905241
Drug reaction with eosinophilia and systemic symptoms 18.09 10.59 11 46708 28477 29877282
Confusional state 17.68 10.59 302 46417 134532 29771227
Blood pressure systolic increased 16.92 10.59 57 46662 15053 29890706
Pancreatic carcinoma metastatic 16.87 10.59 23 46696 3224 29902535
Poor venous access 16.73 10.59 20 46699 2460 29903299
Cytomegalovirus infection 16.70 10.59 8 46711 23666 29882093
Hypersomnia 16.69 10.59 47 46672 11269 29894490
Cerebral haemorrhage 16.67 10.59 16 46703 32871 29872888
Syncope 16.59 10.59 72 46647 84831 29820928
Complication associated with device 16.54 10.59 31 46688 5689 29900070
Eosinophilia 16.39 10.59 7 46712 22153 29883606
Epilepsy 15.52 10.59 6 46713 20163 29885596
Postmortem blood drug level 15.45 10.59 4 46715 16 29905743
Device infusion issue 15.35 10.59 10 46709 544 29905215
Congenital megaureter 15.14 10.59 6 46713 111 29905648
Melaena 15.07 10.59 17 46702 32420 29873339
Psoriasis 15.06 10.59 27 46692 42479 29863280
Intentional overdose 15.01 10.59 26 46693 41455 29864304
Device kink 15.01 10.59 10 46709 565 29905194
Small intestinal obstruction 14.83 10.59 51 46668 13608 29892151
Heart rate increased 14.61 10.59 107 46612 38614 29867145
Bone marrow failure 14.51 10.59 15 46704 29770 29875989
Child abuse 14.42 10.59 7 46712 214 29905545
Device computer issue 14.41 10.59 4 46715 22 29905737
Gastrointestinal haemorrhage 14.41 10.59 74 46645 83372 29822387
Paranasal sinus discomfort 14.31 10.59 10 46709 611 29905148
Suicide attempt 14.22 10.59 22 46697 36675 29869084
Device failure 13.96 10.59 17 46702 2131 29903628
Angioedema 13.92 10.59 20 46699 34364 29871395
Appendicitis 13.82 10.59 30 46689 6114 29899645
Pulse absent 13.80 10.59 28 46691 5445 29900314
Somnolence 13.51 10.59 219 46500 96544 29809215
Microembolism 13.35 10.59 4 46715 30 29905729
Pneumocystis jirovecii pneumonia 13.33 10.59 5 46714 17115 29888644
Urinary tract disorder 13.21 10.59 16 46703 1995 29903764
Body temperature decreased 13.18 10.59 39 46680 9616 29896143
Oesophageal mucosa erythema 13.12 10.59 4 46715 32 29905727
Foreign body embolism 13.11 10.59 3 46716 6 29905753
Drug tolerance increased 13.09 10.59 8 46711 389 29905370
Lung disorder 13.04 10.59 18 46701 31451 29874308
Metastases to chest wall 12.71 10.59 4 46715 36 29905723
Apnoeic attack 12.65 10.59 7 46712 282 29905477
Administration related reaction 12.59 10.59 5 46714 93 29905666
Pelvic pain 12.48 10.59 16 46703 2113 29903646
Reading disorder 12.26 10.59 7 46712 300 29905459
Harlequin syndrome 12.25 10.59 3 46716 9 29905750
Altered state of consciousness 12.22 10.59 8 46711 19911 29885848
Haemorrhoids thrombosed 12.20 10.59 6 46713 189 29905570
Implant site extravasation 12.19 10.59 8 46711 441 29905318
Product prescribing error 12.11 10.59 55 46664 16678 29889081
Anaemia of malignant disease 12.09 10.59 8 46711 447 29905312
Injection site mass 12.09 10.59 25 46694 4928 29900831
Hypoglycaemia 12.05 10.59 40 46679 50941 29854818
Therapeutic product effect decreased 11.93 10.59 82 46637 28994 29876765
Hallucination 11.92 10.59 123 46596 48936 29856823
Chylothorax 11.79 10.59 9 46710 631 29905128
Post-thoracotomy pain syndrome 11.75 10.59 4 46715 47 29905712
Microangiopathic haemolytic anaemia 11.75 10.59 10 46709 819 29904940
Pathological fracture 11.48 10.59 22 46697 4104 29901655
Facet joint syndrome 11.41 10.59 6 46713 218 29905541
Device physical property issue 11.38 10.59 9 46710 665 29905094
Product use in unapproved indication 11.27 10.59 68 46651 73625 29832134
Hepatitis 11.19 10.59 11 46708 22345 29883414
Osteomyelitis 11.18 10.59 49 46670 14632 29891127
Diffuse large B-cell lymphoma recurrent 11.15 10.59 15 46704 2077 29903682
Autoimmune lung disease 11.04 10.59 3 46716 15 29905744
Dehydration 10.94 10.59 261 46458 123278 29782481
Neoplasm of thymus 10.88 10.59 3 46716 16 29905743
Oral candidiasis 10.87 10.59 40 46679 11031 29894728
Post procedural haemorrhage 10.84 10.59 32 46687 7878 29897881
Narcotic bowel syndrome 10.84 10.59 5 46714 136 29905623
Implant site infection 10.77 10.59 10 46709 919 29904840
Spinal cord compression 10.76 10.59 20 46699 3646 29902113
Intentional product use issue 10.65 10.59 95 46624 36345 29869414
Tibia fracture 10.60 10.59 12 46707 1393 29904366

Pharmacologic Action:

SourceCodeDescription
ATC N02AA03 NERVOUS SYSTEM
ANALGESICS
OPIOIDS
Natural opium alkaloids
ATC N02AA53 NERVOUS SYSTEM
ANALGESICS
OPIOIDS
Natural opium alkaloids
ATC N02AG04 NERVOUS SYSTEM
ANALGESICS
OPIOIDS
Opioids in combination with antispasmodics
FDA MoA N0000175684 Full Opioid Agonists
FDA EPC N0000175690 Opioid Agonist
CHEBI has role CHEBI:35482 narcotic analgesics
CHEBI has role CHEBI:55322 mu opioid agonist
MeSH PA D000700 Analgesics
MeSH PA D000701 Analgesics, Opioid
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D009294 Narcotics
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D018689 Sensory System Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Pain indication 22253000
Cough indication 49727002
Severe pain indication 76948002
Common cold indication 82272006 DOID:10459
Acute postoperative pain indication 107401000119105
Severe Pain with Opioid Tolerance indication
Chronic Pain with Opioid Tolerance indication
Suicidal thoughts contraindication 6471006
Dependent drug abuse contraindication 6525002
Alcohol withdrawal delirium contraindication 8635005
Asthenia contraindication 13791008
Constipation contraindication 14760008 DOID:2089
Mood swings contraindication 18963009
Inflammatory bowel disease contraindication 24526004 DOID:0050589
Alcohol intoxication contraindication 25702006
Complete atrioventricular block contraindication 27885002
Shock contraindication 27942005
Hypercapnia contraindication 29596007
Dehydration contraindication 34095006
Disorder of gallbladder contraindication 39621005 DOID:0060262
Hypothyroidism contraindication 40930008 DOID:1459
Conduction disorder of the heart contraindication 44808001
Low blood pressure contraindication 45007003
Bradycardia contraindication 48867003
Hepatic failure contraindication 59927004
Ulcerative colitis contraindication 64766004 DOID:8577
Substance abuse contraindication 66214007
Benign intracranial hypertension contraindication 68267002 DOID:11459
Urethral stricture contraindication 76618002
Decreased respiratory function contraindication 80954004
Injury of head contraindication 82271004
Cor pulmonale contraindication 83291003 DOID:8515
Pulmonary emphysema contraindication 87433001
Kidney disease contraindication 90708001 DOID:557
Acute abdominal pain contraindication 116290004
Neoplasm of brain contraindication 126952004 DOID:1319
Seizure disorder contraindication 128613002
Drug-induced psychosis contraindication 191483003 DOID:1742
Disease of liver contraindication 235856003 DOID:409
Morbid obesity contraindication 238136002 DOID:11981
Sepsis syndrome contraindication 238150007
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Exacerbation of asthma contraindication 281239006
Lesion of brain contraindication 301766008
Deficiency of cholinesterase contraindication 360607009
Coma contraindication 371632003
Primary adrenocortical insufficiency contraindication 373662000
Operation on gastrointestinal tract contraindication 386621005
Hypoxia contraindication 389086002
Central nervous system depression contraindication 418072004
Dysfunction of sphincter of Oddi contraindication 430887001

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.67 acidic
pKa2 8.64 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Mu-type opioid receptor GPCR AGONIST Ki 9.55 CHEMBL CHEMBL
Kappa-type opioid receptor GPCR Ki 8.55 CHEMBL
Delta-type opioid receptor GPCR Ki 7.42 CHEMBL
Opioid receptor GPCR EC50 9 CHEMBL

External reference:

IDSource
4019779 VUID
N0000147870 NUI
D00839 KEGG_DRUG
71-68-1 SECONDARY_CAS_RN
4018035 VANDF
4019779 VANDF
C0012306 UMLSCUI
CHEBI:5790 CHEBI
CHEMBL398707 ChEMBL_ID
CHEMBL1237055 ChEMBL_ID
DB00327 DRUGBANK_ID
D004091 MESH_DESCRIPTOR_UI
5284570 PUBCHEM_CID
7082 IUPHAR_LIGAND_ID
1770 INN_ID
Q812464R06 UNII
203177 RXNORM
1470 MMSL
4848 MMSL
7015 MMSL
d00255 MMSL
001547 NDDF
004622 NDDF
387485001 SNOMEDCT_US
414428000 SNOMEDCT_US
44508008 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Hydromorphone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0054-0264 TABLET 4 mg ORAL ANDA 33 sections
Hydromorphone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0054-0265 TABLET 8 mg ORAL ANDA 33 sections
Hydromorphone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0054-0386 SOLUTION 1 mg ORAL ANDA 33 sections
Hydromorphone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0406-3243 TABLET 2 mg ORAL ANDA 35 sections
Hydromorphone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0406-3244 TABLET 4 mg ORAL ANDA 35 sections
Hydromorphone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0406-3249 TABLET 8 mg ORAL ANDA 35 sections
Hydromorphone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-1283 INJECTION, SOLUTION 1 mg INTRAMUSCULAR NDA 35 sections
Hydromorphone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-1283 INJECTION, SOLUTION 1 mg INTRAMUSCULAR NDA 35 sections
Hydromorphone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-1304 INJECTION, SOLUTION 4 mg INTRAMUSCULAR NDA 33 sections
Hydromorphone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-1312 INJECTION, SOLUTION 2 mg INTRAMUSCULAR NDA 35 sections
Hydromorphone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-1312 INJECTION, SOLUTION 2 mg INTRAMUSCULAR NDA 35 sections
Hydromorphone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-1380 INJECTION, SOLUTION 4 mg INTRAMUSCULAR NDA 35 sections
Hydromorphone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-2540 INJECTION, SOLUTION 4 mg INTRAMUSCULAR NDA 33 sections
Hydromorphone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-2552 INJECTION, SOLUTION 1 mg INTRAMUSCULAR NDA 33 sections
Hydromorphone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-2634 INJECTION, SOLUTION 10 mg INTRAMUSCULAR ANDA 34 sections
Hydromorphone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-3356 INJECTION, SOLUTION 2 mg INTRAMUSCULAR NDA 33 sections
Hydromorphone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-3365 INJECTION, SOLUTION 2 mg INTRAMUSCULAR NDA 33 sections
Hydromorphone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-3459 INJECTION, SOLUTION 2 mg INTRAMUSCULAR UNULLPPROVED DRUG FOR USE IN DRUG SHORTAGE 2 sections
Hydromorphone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-1353 TABLET 2 mg ORAL ANDA 32 sections
Hydromorphone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-1354 TABLET 4 mg ORAL ANDA 32 sections
Hydromorphone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-1355 TABLET 8 mg ORAL ANDA 32 sections
Hydromorphone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-1873 SOLUTION 5 mg ORAL ANDA 30 sections
hydromorphone hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0574-0293 TABLET, EXTENDED RELEASE 8 mg ORAL ANDA 33 sections
hydromorphone hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0574-0294 TABLET, EXTENDED RELEASE 12 mg ORAL ANDA 33 sections
hydromorphone hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0574-0295 TABLET, EXTENDED RELEASE 16 mg ORAL ANDA 33 sections
hydromorphone hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0574-0297 TABLET, EXTENDED RELEASE 32 mg ORAL ANDA 33 sections
HYDROMORPHONE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0574-7224 SUPPOSITORY 3 mg RECTAL Unapproved drug other 35 sections
Hydromorphone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0641-0121 INJECTION 2 mg INTRAMUSCULAR UNULLPPROVED DRUG OTHER 16 sections
Hydromorphone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0641-2341 INJECTION 2 mg INTRAMUSCULAR UNULLPPROVED DRUG OTHER 16 sections
Hydromorphone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0641-6151 INJECTION 2 mg INTRAMUSCULAR ANDA 27 sections